抗VEGF-D抗体(Anti-VEGF-D, Human, Mouse-Mono, Biotin antibody)
掲載日情報:2021/01/28 現在Webページ番号:29846
VEGF-Dに対する抗体(Anti-VEGF-D, Human, Mouse-Mono, Biotin )です。
※ 本製品は研究用です。研究用以外には使用できません。
追加しました。
-
2025/12/01
試薬 特別価格
[RSD]厳選 抗体&リコンビナントタンパク質 30%OFFキャンペーン[~2026/02/27]
期間:2025/12/01 ~2026/02/27
R&D Systems, Inc.(RSD)
- 価格
- Product Details
- Applications and Data
- References
- Related Research Areas
- Related Product & Information
価格
[在庫・価格 :2025年12月03日 15時55分現在]
| 詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Anti-VEGF-D, Human, Mouse-Mono(78923), Biotin |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[在庫・価格 :2025年12月03日 15時55分現在]
Anti-VEGF-D, Human, Mouse-Mono(78923), Biotin
文献数: 0
- 商品コード:BAM286
- メーカー:RSD
- 包装:250μg
-
価格:
¥91,000特別価格 ¥63,700 - 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
| キャンペーン期間 |
2025/12/01 ~ 2026/02/27
[RSD]厳選 抗体&リコンビナントタンパク質 30%OFFキャンペーン[~2026/02/27] |
||
|---|---|---|---|
| 説明文 | マッチドペア:Human VEGF-D サンドイッチELISAの検出用抗体として利用可能,補足用抗体として#MAB2861-500,スタンダードとして#622-VD-005を用いる。 別名:c-fos induced growth factor (vascular endothelial growth factor D) クローン:78923 Genbank No: 2277 Protein Accession No: O43915 |
||
| 法規制等 | |||
| 保存条件 | -20℃ | 法規備考 | |
| 抗原種 | Human | 免疫動物 | Mouse |
| 交差性 | Human | 適用 | ELISA,Western Blot |
| 標識 | Biotin | 性状 | Protein A/G Affinity Purified |
| 吸収処理 | クラス | IgG | |
| クロナリティ | Monoclonal | フォーマット | |
| 掲載カタログ |
|
||
| 製品記事 | Myeloid-derived Suppressor Cell Marker |
||
| 関連記事 | R&D Systems(R&Dシステムズ)社 ELISA用ペア抗体を使用したELISA 構築ガイド |
||
追加しました。
Product Details
| Species Reactivity | Human |
|---|---|
| Label | Biotin |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant human VEGF-DPhe93-Ser201Accession # O43915 |
| Source | Monoclonal Mouse IgG1 Clone # 78923 |
| Purification | Protein A or G purified from ascites |
| Specificity | Detects human VEGF-D in ELISAs and Western blots. In Western blots, this antibody shows approximately 2% cross-reactivity with recombinant mouse (rm) VEGF‑D and no cross-reactivity with rhVEGF165, rmVEGF165, rhVEGF-B186, rmVEGF-B186, rhVEGF206, rhVEGF-C, rhCTGF, or rhPlGF. |
追加しました。
Applications and Data
| Recommended Concentration | Sample | |
| Western Blot | 1 µg/mL | Recombinant Human VEGF-D (Catalog # 622-VD) |
| Human VEGF-D Sandwich Immunoassay | Reagent | |
| ELISA Capture (Matched Antibody Pair) | 2-8 µg/mL | Human VEGF‑D Antibody (Catalog #MAB2861 ) |
| ELISA Detection (Matched Antibody Pair) | 0.5-2.0 µg/mL | Human VEGF‑D Biotinylated Antibody (Catalog #BAM286 ) |
| ELISA Standard | Recombinant Human VEGF-D Protein (Catalog #622-VD ) | |
| Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website. | Preparation and Storage | |
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. | Reconstitution Buffer Available |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. | |
| 1 month, 2 to 8 °C under sterile conditions after reconstitution. | ||
| 6 months, -20 to -70 °C under sterile conditions after reconstitution. | ||
| Background: VEGF-D | Vascular endothelial growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cystine knot structure (1 - 3). VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C‑terminal propeptide extensions around the VEGF homology domain (VHD) (1, 2). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD (4 - 6). Mature human VEGF-D shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively (4, 5). It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin (1 - 4). Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3, also called Flt-4) that are active across species and show enhanced affinity when processed (7). Processed human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR (7). VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium (1, 2). While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth (8 - 10). Both promote tumor lymphangiogenesis (11). Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF R3 signaling in lymphangiogenesis, while binding to integrin alpha 9 beta 1 mediates endothelial cell adhesion and migration (12, 13).
|
|
追加しました。
References
| Roy, H. et al. (2006) FEBS Lett. 580:2879. | |
| Otrock, Z.H. et al. (2007) Blood Cells Mol. Dis. 38:258. | |
| Yamada, Y. et al. (1997) Genomics 42:483. | |
| Stacker, S.A. et al. (1999) J. Biol. Chem. 274:32127. | |
| McColl, B.K. et al. (2003) J. Exp. Med. 198:863. | |
| McColl, B.K. et al. (2007) FASEB J. 21:1088. | |
| Baldwin, M.E. et al. (2001) J. Biol. Chem. 276:19166. | |
| Baldwin, M.E. et al. (2005) Mol. Cell. Biol. 25:2441. | |
| Karpanen, T. et al. (2006) Am. J. Pathol. 169:708. | |
| Orlandini, M. et al. (2006) J. Biol. Chem. 281:17961. | |
| Stacker, S.A. et al. (2001) Nature Med. 7:186. | |
| Karpanen, T. et al. (2006) FASEB J. 20:1462. | |
| Vlahakis, N.E. et al. (2005) J. Biol. Chem. 280:4544. | |
| Long Name: | Vascular Endothelial Growth Factor D/cFos-induced Growth Factor |
| Entrez Gene IDs: | 2277 (Human); 14205 (Mouse) |
| Alternate Names: | c-fos induced growth factor (vascular endothelial growth factor D); FIGF; vascular endothelial growth factor D; VEGFD; VEGF-D; VEGF-DVEGFDc-Fos-induced growth factor |
追加しました。
Related Research Areas
| VEGF Family |
| VEGF Family Ligands |
追加しました。
Related Product & Information
| Background | VEGF-D |
|---|---|
| background_content | Background: VEGF-D Vascular endothelial growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cystine knot structure (1 - 3). VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C‑terminal propeptide extensions around the VEGF homology domain (VHD) (1, 2). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD (4 - 6). Mature human VEGF-D shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively (4, 5). It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin (1 - 4). Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3, also called Flt-4) that are active across species and show enhanced affinity when processed (7). Processed human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR (7). VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium (1, 2). While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth (8 - 10). Both promote tumor lymphangiogenesis (11). Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF R3 signaling in lymphangiogenesis, while binding to integrin alpha 9 beta 1 mediates endothelial cell adhesion and migration (12, 13). |
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。
